Get the app
US › Healthcare

Standard Biotools Inc (LAB)

US · Healthcare · Medical Devices

$0.73+2.82%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$20.1M
Revenue YoY
-7.6%
Net profit
$-26.8M
EPS
$-0.05
EPS estimate
$-0.03
Net margin
-133.1%

EPS came in at -0.05 against a street estimate of -0.03 — a miss of 66.7%.

Key statistics

Market cap
$270.8M
Forward P/E
0.0
P/B
0.53
Book value
$1.38
EPS (TTM)
$-0.13
52-week high
$1.72
52-week low
$0.63
50-day MA
$0.78
200-day MA
$1.05
Beta
1.37

Analyst view

Analysts rate Standard Biotools Inc a buy (2 buy, 1 hold, 0 sell out of 3) with an average price target of $1.35.

Shareholding

Insiders
2.02%
Institutions
76.04%

Largest institutional holders

FundStake
Casdin Capital, LLC22.64%
Viking Global Investors LP14.96%
Mak Capital One LLC6.67%
BlackRock Inc6.31%
Long Focus Capital Management, LLC5.99%
Vanguard Capital Management, LLC3.27%
Geode Capital Management, LLC1.86%
State Street Corp1.67%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Standard Biotools Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.